Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 48,537 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: AS+ Clear all
Completed Not applicable Interventional Results available

Insomnia Self-Management in Heart Failure

NCT02660385
View directory record Official record
Conditions
Cardiac Failure, Heart Failure, Congestive Heart Failure, Heart Failure, Congestive, Sleep Initiation and Maintenance Disorders, Chronic Insomnia, Disorders of Initiating and Maintaining Sleep, Fatigue, Pain, Depressive Symptoms, Sleep Disorders, Anxiety
Interventions
Cognitive Behavioral Therapy for Insomnia, Self-Management Education for Heart Failure
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 3 Interventional Results available

EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

NCT02234843
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Standard of Care
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Nov 11, 2026, 9:45 PM EST
Terminated Not applicable Interventional

Mindfulness Rounds Initiative - A Short Mindfulness-Based Program for A Busy Workplace

NCT04282733
View directory record Official record
Conditions
Healthcare Practitioner Stress, Patient Satisfaction
Interventions
Mindfulness Rounds
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Nov 11, 2026, 9:45 PM EST
Withdrawn Phase 3 Interventional

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 1 Interventional

Culturally Responsive Person-Centered Care for Psychosis

NCT00231933
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Person-centered planning (PCP), Community integration (CI), Illness management recovery (IMR)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2020 · Synced Nov 11, 2026, 9:45 PM EST
Completed Not applicable Interventional Results available

Internal Radiation Therapy in Treating Patients With Prostate Cancer

NCT00573833
View directory record Official record
Conditions
Prostate Cancer
Interventions
questionnaire administration, quality-of-life assessment, brachytherapy
Other · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 3 Interventional

Seroquel in Bipolar Depression Versus SSRI

NCT00119652
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity
Drug · Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Nov 11, 2026, 9:45 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence

NCT03037749
View directory record Official record
Conditions
Domestic Violence, Alcohol Consumption
Interventions
Alcohol beverage, Placebo beverage
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Nov 11, 2026, 9:45 PM EST
Completed Not applicable Interventional

Optimizing Engagement in Services for First-Episode Psychosis

NCT05310838
View directory record Official record
Conditions
Engagement, Patient, First Episode Psychosis
Interventions
Behavioral Activation for First Episode Psychosis, Treatment As Usual
Behavioral
Lead sponsor
California State University, San Bernardino
Other
Eligibility
15 Years to 35 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Granada Hills, California • Sylmar, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 11, 2026, 9:45 PM EST
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Nov 11, 2026, 9:45 PM EST
Completed No phase listed Observational

Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia

NCT01540578
View directory record Official record
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Nov 11, 2026, 9:45 PM EST
Not yet recruiting Phase 2 Interventional

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia

NCT07920185
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo
Drug
Lead sponsor
Somnum Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 2 Interventional Results available

CEP-701 for PH-negative Myelofibrosis

NCT00494585
View directory record Official record
Conditions
Leukemia, Myelofibrosis
Interventions
CEP-701
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Nov 11, 2026, 9:45 PM EST
Completed No phase listed Observational

Hereditary Parkinson s Disease Natural History Protocol

NCT02511015
View directory record Official record
Conditions
Parkinson Disease 6, Early-Onset, Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human, Parkinson Disease Autosomal Recessive, Early Onset, Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contrast-enhanced Ultrasound of the Kidney

NCT02684435
View directory record Official record
Conditions
Chronic Kidney Disease, Cystic Kidney Disease
Interventions
Perflutren lipid microsphere
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 4 Interventional Results available

Predicting Response to Standardized Pediatric Colitis Therapy

NCT01536535
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy
Drug · Other · Procedure
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
4 Years to 17 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Nov 11, 2026, 9:45 PM EST
Completed No phase listed Observational

Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy

NCT01698515
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Nov 11, 2026, 9:45 PM EST
Completed No phase listed Observational

Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations

NCT04509115
View directory record Official record
Conditions
Opioid Use, Opioid Prescribing
Interventions
Short-acting opioid prescription for acute pain
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Nov 11, 2026, 9:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Project PRIDE (Promoting Resilience In Discriminatory Environments)

NCT03528135
View directory record Official record
Conditions
Human Immunodeficiency Virus, Sexually Transmitted Infections, Anxiety, Depression, Substance Use Disorders
Interventions
Project PRIDE
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 25 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 1 Interventional

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Nov 11, 2026, 9:45 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bad Breath Response to Tongue Scraper and Rinses

NCT00867035
View directory record Official record
Conditions
Halitosis
Interventions
Chlorine dioxide and scraper, Chlorhexidine gluconate and scraper
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 16, 2013 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 1 Interventional

A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer

NCT02048384
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
metformin alone (Arm A), metformin (Arm B), rapamycin (Arm B)
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Nov 11, 2026, 9:45 PM EST
Withdrawn Phase 4 Interventional

Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care

NCT02324933
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Fentanyl
Drug
Lead sponsor
Bassett Healthcare
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Cooperstown, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Nov 11, 2026, 9:45 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

NCT04083833
View directory record Official record
Conditions
TQT Study
Interventions
Tetrodotoxin, Placebos
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Nov 11, 2026, 9:45 PM EST